Recombinant Human Endostatin - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509241808

Publication Date:

September 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. Human monomeric endostatin is a globular protein containing two disulfide bonds: Cys162鈭�302 and Cys264鈭�294.
The global market for Recombinant Human Endostatin was estimated to be worth US$ 130 million in 2023 and is forecast to a readjusted size of US$ 238 million by 2030 with a CAGR of 8.0% during the forecast period 2024-2030
The market for recombinant human endostatin is important in cancer treatment. Trends include research into combination therapies and targeted cancer treatments.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Endostatin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant Human Endostatin by region & country, by Type, and by Application.
The Recombinant Human Endostatin market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Endostatin.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
PeproTech
Segment by Type:
Purity:95%
Others
Segment by Application
Medical Care
Scientific Research
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Human Endostatin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant Human Endostatin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant Human Endostatin in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Recombinant Human Endostatin Product Introduction
1.2 Global Recombinant Human Endostatin 麻豆原创 Size Forecast
1.2.1 Global Recombinant Human Endostatin Sales Value (2019-2030)
1.2.2 Global Recombinant Human Endostatin Sales Volume (2019-2030)
1.2.3 Global Recombinant Human Endostatin Sales Price (2019-2030)
1.3 Recombinant Human Endostatin 麻豆原创 Trends & Drivers
1.3.1 Recombinant Human Endostatin Industry Trends
1.3.2 Recombinant Human Endostatin 麻豆原创 Drivers & Opportunity
1.3.3 Recombinant Human Endostatin 麻豆原创 Challenges
1.3.4 Recombinant Human Endostatin 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Human Endostatin Players Revenue Ranking (2023)
2.2 Global Recombinant Human Endostatin Revenue by Company (2019-2024)
2.3 Global Recombinant Human Endostatin Players Sales Volume Ranking (2023)
2.4 Global Recombinant Human Endostatin Sales Volume by Company Players (2019-2024)
2.5 Global Recombinant Human Endostatin Average Price by Company (2019-2024)
2.6 Key Manufacturers Recombinant Human Endostatin Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Recombinant Human Endostatin Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Recombinant Human Endostatin
2.9 Recombinant Human Endostatin 麻豆原创 Competitive Analysis
2.9.1 Recombinant Human Endostatin 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant Human Endostatin Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human Endostatin as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Purity:95%
3.1.2 Others
3.2 Global Recombinant Human Endostatin Sales Value by Type
3.2.1 Global Recombinant Human Endostatin Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Human Endostatin Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Human Endostatin Sales Value, by Type (%) (2019-2030)
3.3 Global Recombinant Human Endostatin Sales Volume by Type
3.3.1 Global Recombinant Human Endostatin Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Recombinant Human Endostatin Sales Volume, by Type (2019-2030)
3.3.3 Global Recombinant Human Endostatin Sales Volume, by Type (%) (2019-2030)
3.4 Global Recombinant Human Endostatin Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Medical Care
4.1.2 Scientific Research
4.1.3 Others
4.2 Global Recombinant Human Endostatin Sales Value by Application
4.2.1 Global Recombinant Human Endostatin Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Human Endostatin Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Human Endostatin Sales Value, by Application (%) (2019-2030)
4.3 Global Recombinant Human Endostatin Sales Volume by Application
4.3.1 Global Recombinant Human Endostatin Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Recombinant Human Endostatin Sales Volume, by Application (2019-2030)
4.3.3 Global Recombinant Human Endostatin Sales Volume, by Application (%) (2019-2030)
4.4 Global Recombinant Human Endostatin Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Human Endostatin Sales Value by Region
5.1.1 Global Recombinant Human Endostatin Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Human Endostatin Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Human Endostatin Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Human Endostatin Sales Value by Region (%), (2019-2030)
5.2 Global Recombinant Human Endostatin Sales Volume by Region
5.2.1 Global Recombinant Human Endostatin Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Recombinant Human Endostatin Sales Volume by Region (2019-2024)
5.2.3 Global Recombinant Human Endostatin Sales Volume by Region (2025-2030)
5.2.4 Global Recombinant Human Endostatin Sales Volume by Region (%), (2019-2030)
5.3 Global Recombinant Human Endostatin Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Recombinant Human Endostatin Sales Value, 2019-2030
5.4.2 North America Recombinant Human Endostatin Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Recombinant Human Endostatin Sales Value, 2019-2030
5.5.2 Europe Recombinant Human Endostatin Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Recombinant Human Endostatin Sales Value, 2019-2030
5.6.2 Asia Pacific Recombinant Human Endostatin Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Recombinant Human Endostatin Sales Value, 2019-2030
5.7.2 South America Recombinant Human Endostatin Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Recombinant Human Endostatin Sales Value, 2019-2030
5.8.2 Middle East & Africa Recombinant Human Endostatin Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Human Endostatin Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Human Endostatin Sales Value
6.2.1 Key Countries/Regions Recombinant Human Endostatin Sales Value, 2019-2030
6.2.2 Key Countries/Regions Recombinant Human Endostatin Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Recombinant Human Endostatin Sales Value, 2019-2030
6.3.2 United States Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Human Endostatin Sales Value, 2019-2030
6.4.2 Europe Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Human Endostatin Sales Value, 2019-2030
6.5.2 China Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Human Endostatin Sales Value, 2019-2030
6.6.2 Japan Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Human Endostatin Sales Value, 2019-2030
6.7.2 South Korea Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Human Endostatin Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Human Endostatin Sales Value, 2019-2030
6.9.2 India Recombinant Human Endostatin Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Human Endostatin Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Company Information
7.1.2 Thermo Fisher Scientific Introduction and Business Overview
7.1.3 Thermo Fisher Scientific Recombinant Human Endostatin Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Thermo Fisher Scientific Recombinant Human Endostatin Product Offerings
7.1.5 Thermo Fisher Scientific Recent Development
7.2 PeproTech
7.2.1 PeproTech Company Information
7.2.2 PeproTech Introduction and Business Overview
7.2.3 PeproTech Recombinant Human Endostatin Sales, Revenue and Gross Margin (2019-2024)
7.2.4 PeproTech Recombinant Human Endostatin Product Offerings
7.2.5 PeproTech Recent Development
8 Industry Chain Analysis
8.1 Recombinant Human Endostatin Industrial Chain
8.2 Recombinant Human Endostatin Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Human Endostatin Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Human Endostatin Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Thermo Fisher Scientific
PeproTech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.